Tag Archives: Cipla

Deferacirox-composition-pregrant oppoisition-india

A new pre grant opposition decision is uploaded in IPO site. Application NO: 593/CHENP/2005 is assigned to Novartis and Titled “Dispersible tablets comprising deferacirox”. This application is opposed by Cipla under 25(1). This application is refused under lack of inventive … Continue reading

Posted in Patent case | Tagged , , , | Leave a comment

CL application for Raltegravir in India

Toady SpicyIP reported filing of compulsory license for Raltegravir by Cipla [SpicyIP] Some additional info: Raltegravir seems to be protected by 212400 (868/CHENP/2004) assigned to Istituto Di Ricerche Di Biologia/Merck, which is granted on 10/01/2008. [Patentcircle] [i-mak]

Posted in Patent case | Tagged , , , | Leave a comment

India: Lopinavir+Ritonavir Abbott Application Rejected

Formulation patent application which covers Lopinavir+Ritonavir combination is rejected in India. This application was opposed by i-mak, Matrix, Cipla and Osaka. Application No: 339/MUMNP/2006 (National phase of WO2005/039551) Applicant: Abbott Opponents: i-mak, Cipla, Matrix, Osaka Interesting Note: This application is related … Continue reading

Posted in Patent case | Tagged , , , , , , | Leave a comment

Roche Erlotinib Patent suit brief

Roche is an exclusive licensee for Erlitinib hydrochloride in india and patent details are below: Granted patent: IN196774 Grant Publication: 14/Sep/2007 Application: 537/DEL/1996 Applicant: Pfizer Corresponding patent: US5747498 [Orange Book listed] US expiry: 30/Mar/2015 Erlotinib was developed jointly by OSI … Continue reading

Posted in Patent case | Tagged , , , | 1 Comment